Taylor H R, Greene B M, Langham M E
Lancet. 1980 May 3;1(8175):943-6. doi: 10.1016/s0140-6736(80)91402-6.
In a double-blind controlled clinical trial comparing the safety and efficacy of oral diethylcarbamazine citrate (DEC) with topical DEC for the treatment of onchocerciasis twenty men with moderate skin-snip microfilarial counts received daily therapy for 1 week, then weekly therapy for the rest of 6 months. The number of microfilariae per skin snip dropped quickly to 2% of initial levels and remained at low levels in those receiving oral DEC, and to 20% of initial levels in patients treated with DEC lotion. Side-effects in both groups included lymphadenopathy, fever, pruritus, rash, proteinuria, and chorioretinitis; they were commoner with topical DEC.
在一项双盲对照临床试验中，为比较口服枸橼酸乙胺嗪（DEC）与外用DEC治疗盘尾丝虫病的安全性和疗效，20名皮肤切片微丝蚴计数中等的男性接受了为期1周的每日治疗，然后在接下来的6个月中接受每周治疗。在接受口服DEC的患者中，每次皮肤切片的微丝蚴数量迅速降至初始水平的2%，并维持在低水平；而在用DEC洗剂治疗的患者中，该数量降至初始水平的20%。两组的副作用均包括淋巴结病、发热、瘙痒、皮疹、蛋白尿和脉络膜视网膜炎；外用DEC的副作用更常见。
